Found 1,760 articles
Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares of its common stock at a purchase price of $5.65 per share and associated Common Warrant.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement therapies in development for the treatment of mucopolysaccharidoses (MPS).
Co-Diagnostics, Inc. announced the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company's vision.
Household Income and Health Insurance Among Factors in Decision to Withdraw Life Support After Hemorrhagic Stroke
Living in a high-income neighborhood, having private health insurance, and being older are tied to an increased likelihood that life support will be withdrawn for people who have suffered severe bleeding in the brain, a new study shows.
Leaders at City of Hope forecast that in 2024 more people will benefit from cancer breakthroughs, including research that unlocks the biology behind cancer disparities, wider access to CAR T cell therapy and rapid whole genome sequencing.
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society Annual Meeting January 18-21 in Las Vegas.
Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause
Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant.
Benson Hill Announces Gains in Soybean Breeding Program; Introduces Five 2024 Soybean Varieties Delivering Higher Protein and Improved Yield Potential
Benson Hill, Inc., an ag tech company unlocking the natural genetic diversity of plants, announced that recent advances in its soybean breeding program will drive the doubling of its seed portfolio by 2025.
BioCT, the life sciences trade association for Connecticut, is thrilled to name Stephen Bloch, MD, the 2023 BioCT Entrepreneur of the Year, an award recognizing individuals who are imaginative, passionate, and game-changers in Connecticut bioscience.
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Novartis announced results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta® in adults with paroxysmal nocturnal hemoglobinuria who had residual anemia despite previous anti-C5 therapy.
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1.
PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium
Prelude Corporation announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy in ductal carcinoma in situ patients in Australia.
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the JAMA
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd announced the publication of the final overall survival results from the pivotal JUPITER-02 study.
Prelude Corporation today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).
Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or CRNM Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced during a Late-Breaking session of the American Heart Association meeting that abelacimab demonstrated a highly significant reduction in bleeding events across all primary and secondary endpoints versus a standard of care direct-oral anticoagulant.
Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, reported financial results for the third quarter ended September 30, 2023.
Masimo announced that Rolf A. Classon has been appointed to Masimo’s Board of Directors.